Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma

Abstract Orthostatic hypotension (OH) is a well-recognized phenomenon occurring in multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT), and is associated with significant morbidity and mortality. A retrospective analysis of patients admitted for first ASCT between June 2012 and April 2014 found that 161/222 (73%) patients were diagnosed with OH during the course of ASCT, including 51 patients who were found to have OH on the day of first orthostatic vitals check. Excluding these 51 patients, 110/171 (64%) patients developed OH during the peri-transplant period, at a median of 7 days post ASCT (95% CI: 6.5–8.5). OH did not significantly impact length of hospitalization, progression free and overall survival. Multivariable analysis revealed four risk factors (i.e. ≥0.5% weight loss/day, white race, gabapentin, antihypertensives) and two protective factors (i.e. antihistamine, proton pump inhibitor) associated with the development of peri-transplant OH.

[1]  J. Canada,et al.  Orthostatic intolerance syndromes after hematopoietic cell transplantation: clinical characteristics and therapeutic interventions in a single-center experience , 2021, Cardio-Oncology.

[2]  P. Richardson,et al.  The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift? , 2020, British journal of haematology.

[3]  C. Tseng,et al.  Gabapentin Reduces Blood Pressure and Heart Rate through the Nucleus Tractus Solitarii. , 2019, Acta Cardiologica Sinica.

[4]  P. Richardson,et al.  How I treat the young patient with multiple myeloma. , 2018, Blood.

[5]  S. Rajkumar,et al.  Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management , 2018, American journal of hematology.

[6]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[7]  J. Lund,et al.  Gabapentin for the hemodynamic response to intubation: systematic review and meta-analysis , 2016, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[8]  H. Enright,et al.  Increased incidence of symptomatic postural hypotension in multiple myeloma patients treated with subcutaneous bortezomib , 2015 .

[9]  I. Bala,et al.  Effect of gabapentin pretreatment on the hemodynamic response to laryngoscopy and tracheal intubation in treated hypertensive patients. , 2015, Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists.

[10]  A. Chari,et al.  Outcome of patients with multiple myeloma and hypotension during high‐dose chemotherapy , 2015, American journal of hematology.

[11]  P. Rosenberg,et al.  Future distribution of multiple myeloma in the United States by sex, age, and race/ethnicity. , 2015, Blood.

[12]  Hans Erik Johnsen,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[13]  V. Ayatollahi,et al.  Effect of oral gabapentin on haemodynamic variables during microlaryngoscopic surgery. , 2014, Anaesthesiology intensive therapy.

[14]  A. Chari,et al.  Incidence Of Hypotension In Patients With Multiple Myeloma During High Dose Chemotherapy and Autologous Stem Cell Rescue , 2013 .

[15]  B. Pégourié,et al.  Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Wenning,et al.  Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management , 2012, Journal of Neurology.

[17]  I. Katona,et al.  Bortezomib-induced severe autonomic neuropathy , 2012, Clinical Autonomic Research.

[18]  E. Paul,et al.  Prevalence, associations, and risk factors for orthostatic hypotension in medical, surgical, and trauma inpatients: an observational cohort study. , 2012, The Ochsner journal.

[19]  L. Krakoff,et al.  Morbidity and mortality of orthostatic hypotension: implications for management of cardiovascular disease. , 2011, American journal of hypertension.

[20]  A. Sharrett,et al.  Orthostatic Hypotension Predicts Mortality in Middle-Aged Adults: The Atherosclerosis Risk in Communities (ARIC) Study , 2006, Circulation.

[21]  J. Halliwill,et al.  H1 receptor‐mediated vasodilatation contributes to postexercise hypotension , 2005, The Journal of physiology.

[22]  M. Ziegler,et al.  The causes of postural cardiovascular disorders. , 2005, Hypertension.

[23]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Morgan,et al.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.

[25]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[26]  A. Weiss,et al.  Orthostatic hypotension in acute geriatric ward: is it a consistent finding? , 2002, Archives of internal medicine.

[27]  E. Wagner,et al.  Correlates of Postural Hypotension in a Community Sample of Elderly Blacks and Whites , 1991, Journal of the American Geriatrics Society.

[28]  高橋 伸也.  Dimethyl sulfoxide (DMSO). , 1980, The Medical letter on drugs and therapeutics.

[29]  A. Kligman.  Dimethyl Sulfoxide—Part 2 , 1965 .

[30]  A. Kligman.  Topical Pharmacology and Toxicology of Dimethyl Sulfoxide—Part 1 , 1965 .

[31]  A Klestov,et al.  Dimethyl sulfoxide , 2016, Reactions Weekly.

[32]  Z. Akı,et al.  Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia , 2012 .

[33]  P. Sonneveld,et al.  A practical update on the use of bortezomib in the management of multiple myeloma. , 2006, The oncologist.

[34]  A. Kligman.  TOPICAL PHARMACOLOGY AND TOXICOLOGY OF DIMETHYL SULFOXIDE. 1. , 1965, Journal of the American Medical Association (JAMA).

[35]  A. Kligman.  DIMETHYL SULFOXIDE. 2. , 1965, Journal of the American Medical Association (JAMA).